SOURCE: The Medicines Company

The Medicines Company

June 04, 2012 03:00 ET

Cees Heiman Joins The Medicines Company to Lead Europe and Middle East Business

Experienced Global Executive Joins to Drive Regional Growth, Contribute to Global Strategy in Acute and Intensive Care Hospital Medicine

ZURICH, SWITZERLAND--(Marketwire - Jun 4, 2012) - The Medicines Company (NASDAQ: MDCO) today announced the appointment of Cees J. Heiman as Senior Vice President and Regional Engagement Leader for Europe and the Middle East. Mr. Heiman will be based in the Company's European center in Zurich, CH and report to Clive Meanwell, Chairman and Chief Executive Officer in Parsipanny, New Jersey, USA. Mr. Heiman joins the Company from Pfizer where he most recently served as the Regional President of Europe for their Specialty Care Business Unit -- a multi-billion dollar revenue business in hospital and specialty care.

Dr. Meanwell stated, "Our European business is growing strongly and has emerged in the last year as a significant force in acute and intensive care medicine. Cees Heiman's skills, experience, track-record and entrepreneurial mindset promise to contribute even more value and service to leading European hospitals, to our partners and to our growing team. We can also now take on the growth challenge of serving selective parts of the Middle East."

Mr. Heiman said, "This is a rare and exciting opportunity to apply my experience in a dynamic, entrepreneurial and emerging organization. I believe that the portfolio of marketed and development assets and the focus and growth rate driven by an outstanding team throughout most of Europe gives us the opportunity to build a leading company in acute and intensive care hospital medicine in the region. I relish the opportunity to take on the challenge of growth at The Medicines Company. Our global purpose -- save lives, alleviate suffering and improve the economic efficiency of the 3,000 leading acute, intensive care hospitals in the world -- is a major challenge which I believe we can meet together."

Mr. Heiman joined Pfizer in 1982 in the Medical Department of Pfizer Netherlands and served in several assignments in marketing and new product development, first in the Netherlands and later in India as well as at New York headquarters. In 1995, he was named Country Manager of Hungary, and subsequently became Vice President of Marketing and New Product Development for Pfizer Japan. From 2000 until 2004, he held the position of Country Manager of Poland, followed by Country Manager of Belgium/Luxembourg until 2007. He served as Regional President of Pfizer Central and Eastern Europe, a role he assumed in 2007, and was named Country Manager for Italy in 2008. He has served on numerous boards and organizations representing Pfizer in the external marketplace, most recently in the European Federation of Pharmaceutical Industry Associations (EFPIA) as Pfizer's Head of Europe. He is a graduate of the University of Leiden, Netherlands and has a Masters in Pharmacy.

About The Medicines Company
The Medicines Company (NASDAQ: MDCO) provides medical solutions to improve health outcomes for patients in acute and intensive care hospitals worldwide. These solutions comprise medicines and knowledge that directly impact the survival and well-being of critically ill patients. The Medicines Company's website is

Statements contained in this press release about The Medicines Company that are not purely historical, and all other statements that are not purely historical, may be deemed to be forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, the words "believes," "anticipates" and "expects" and similar expressions, including the Company's preliminary revenue results, are intended to identify forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by these forward-looking statements. Important factors that may cause or contribute to such differences include the extent of the commercial success of Angiomax, the Company's ability to develop its global operations and penetrate foreign markets, whether the Company's products will advance in the clinical trials process on a timely basis or at all, whether the Company will make regulatory submissions for product candidates on a timely basis, whether its regulatory submissions will receive approvals from regulatory agencies on a timely basis or at all, whether physicians, patients and other key decision makers will accept clinical trial results, risks associated with the establishment of international operations, whether the Company is able to obtain or maintain patent protection for the intellectual property relating to the Company's products; and such other factors as are set forth in the risk factors detailed from time to time in the Company's periodic reports and registration statements filed with the Securities and Exchange Commission including, without limitation, the risk factors detailed in the Company's Quarterly Report on Form 10-Q filed on May 10, 2012, which are incorporated herein by reference. The Company specifically disclaims any obligation to update these forward-looking statements.

Contact Information